List
The Award database is continually updated throughout the year. As a result, data for FY19 is not expected to be complete until April, 2020.
-
Biocatalytic production of precursors to lutein and zeaxanthin to address age related macular degeneration
SBC: EscaZyme Biochemicals, LLC Topic: NProject Summary Atrophic dry age related macular degeneration AMD is the leading cause of severe loss of vision for those over age Dietary supplements containing lutein and zeaxanthin are recommended by the NEI for those at risk of late AMD There has been a corresponding growth in demand for these two xanthophylls Lutein and zeaxanthin are currently sourced from marigolds grown mostl ...
STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health -
SWIFT ActiveScreener research and development of an intelligent web based document screening system
SBC: Sciome LLC Topic: NIEHSProject Summary More than systematic reviews are performed each year in the fields of environmental health and evidence based medicine with each review requiring on average between six months to one year of effort to complete In order to remain accurate systematic reviews require regular updates after their initial publication with most reviews out of date within five years In the sc ...
SBIR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health -
Clinical evaluation of the novel uni directional Pd CivaSheet for Lung Cancer
SBC: CIVATECH ONCOLOGY, INC. Topic: 102CivaTech Oncology s mission is to provide improved radiation therapy directly to localized tumors The Company has developed a novel polymer encapsulated membrane like radiation source that emits radiation on only one side of the device the CivaSheet This directional source is compatible with open and minimally invasive surgical techniques and has FDA clearance to be used as primary or combin ...
SBIR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health -
Tuned stem cell extracellular vesicles as a novel chronic wound therapeutic
SBC: ZEN-BIO, INC. Topic: NIAProject Summary The elderly population is rapidly increasing worldwide and those over years old are expected to comprise of the total population by These demographic changes will focus healthcare needs on those conditions more prevalent in the elderly Chronic wounds such as venous leg ulcers pressure ulcers and diabetic ulcers are over represented in the elderly population and even ...
SBIR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health -
Validation of a Performance Based Measure of Functioning in MCI and Early AD
SBC: NEUROCOG TRIALS Topic: NIAProject Summary Alzheimer s disease AD is expected to rise in prevalence from to million Americans by leading to of deaths among adults over This epidemic is projected to overwhelm healthcare and economic resources with costs reaching $ billion in the US in and $ trillion by There is no cure for AD and no new drugs have been successful in treating the advance ...
SBIR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health -
Functional Tissue Engineering for Cartilage Repair
SBC: Cytex Therapeutics, Inc. Topic: NIAAbstract It is estimated that only about of young patients suffering from!activity limiting hip osteoarthritis OA choose to undergo traditional hip replacement surgery This low percentage is attributed to the shortened projected lifetime of hip implants for active patients and the subsequent need for revision surgeries that are plagued with higher complication rates and overall decreased ef ...
SBIR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health -
A D osteoarthritis model targeting patient populations with high risk genetic polymorphisms
SBC: Cytex Therapeutics, Inc. Topic: NIAMSAbstract Osteoarthritis OA is a degenerative joint disease that affects an estimated million adults in the United States and results in an economic burden of over $ billion per year Although the burden of OA is immense current non surgical treatments are only palliative and no disease modifying OA drugs DMOADs presently exist to address the problem This lack of success in identifying ...
SBIR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health -
Novel PhageLock assay to measure hepcidin for clinical monitoring
SBC: AFFINERGY, LLC Topic: 400SUMMARY ABSTRACT Hepcidin is the peptide hormone responsible for regulating circulating iron concentrations Overexpression of hepcidin results in severe iron deficiency and anemia whereas hepcidin deficiency leads to iron overload Not surprisingly abnormalities in hepcidin production and circulating concentrations are highly correlated with various disease states such as renal disease cancer ...
SBIR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health -
Implantable iontophoresis chemotherapy delivery device for direct infusion of gemcitabine into pancreatic adenocarcinoma Device development and First in Human clinical trial
SBC: Advanced Chemotherapy Technologies Topic: 102PROJECT SUMMARY Advanced Chemotherapy Technologies ACT has developed a proprietary implantable iontophoretic device that facilitates the infusion of chemotherapy agents directly into a cancer tumor minimizing toxic exposure to the vascular system and other organs ACT is focusing specifically on treating pancreatic cancer with gemcitabine for this proposal Pancreatic cancer has a five year sur ...
SBIR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health -
Ultrasound Based Device to Guide Treatment of Graft Versus Host Disease Using Skin Elasticity as a Biomarker
SBC: Microelastic Ultrasound Systems, Inc. Topic: 102Ultrasound Based Device to Guide Treatment of Graft Versus Host Disease using Skin Elasticity as a Biomarker ABSTRACT Sclerotic chronic graft versus host disease cGVHD develops in of allogenic Human Stem Cell Transplant HCT recipients and is associated with significant morbidity and mortality GVHD is treated with immunosuppression which puts patients at severe risk of infection ...
STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health